



ANIMAL HEALTH  
**CORRIDOR  
SUMMIT**

**2023**

**PRESENTING EMERGING COMPANIES**

**AgLogica Holdings**

**Peachtree Corners, Georgia | [Website](#)**

*AgLogica Holdings, dba AGL Technology, is developing its Precision Farming Intelligence Platform (PFIP) to deliver round-the-clock eyes and ears for food animal production systems. PFIP will monitor animal facilities for health, welfare, and production metrics in order to deliver alerts to managers regarding actionable insights. In addition, the system also provides a means to drill down for more detailed analysis to be performed. Initially designed for poultry, PFIP will allow producers to utilize limited resources to better manage flock livability and optimize growing conditions to add value in the form of a 4:1 return on investment.*

**Akston Biosciences Corporation**

**Beverly, Massachusetts | [Website](#)**

*Akston Biosciences Corporation has developed Ambifect™, a proprietary platform upon which the company is developing long-acting peptide drugs such as insulin, GLP-1, and growth hormones as well as vaccines targeting infectious pathogens and endogenous targets. The platform, utilizing monoclonal antibody production technology, addresses the critical animal health issues of cost of goods, production volume, and long-term temperature stability. With one product already advanced to partnering, the company is looking to expand and accelerate pipeline development.*

**AskVet**

**San Marcos, California | [Website](#)**

*AskVet is scaling and growing VERA, Veterinary Engagement & Relationship Agent. VERA is a digital platform for virtual pet healthcare and wellness. This natural language VetBot will allow pet parents access to immediate, personalized answers to their health, nutrition, behavior, and training questions while allowing veterinary practices to improve client satisfaction while reducing staff workload. In addition, VERA provides a means for pet brands to engage more closely and effectively with their customers. Capable of over 20 languages, the company is positioned to engage the global market with its platform.*



# PRESENTING EMERGING COMPANIES

## Auxilium MD

Richardson, Texas | [Website](#)

*Auxilium MD is focused on providing innovative therapies and devices to the animal health market. A spin-out from Teliatry, Inc., a company in the human space, the company's first product, Milo, targets treatment of epilepsy through a minimally invasive implant. The technology will treat the leading neurological disorder in dogs without the use of pharmaceuticals and their associated side effects. Approved for use in humans, including in pediatrics, the company will bring this small, inexpensive implant to the animal health market to benefit dogs with epilepsy including the one-third of dogs which do not respond to medication.*

## Dexer

Overland Park, Kansas | [Website](#)

*Dexer offers a revolutionary leap forward in data capture. No longer is there a need for manual entry or duplication but one which frees the user to focus on the task at hand. Dexer uses the voice of the user to capture, store, and organize data in real time in an app customized to the needs of the user. The company will build a customized speech app unique to user needs using the data capture form currently used by the client or have the client complete an input template. This allows the platform to accommodate scientific and technical language, a feature unique to Dexer. Once the data is entered, the data is reviewed at the historic data view page where changes can be made and, once complete, uploaded to the cloud where it can be further managed.*

## Full Life Wellness

Phoenix, Arizona | [Website](#)

*Full Life Wellness introduces Artie™. Artie is the only pet food system that allows preparation of artisan-inspired, home-cooked meals at the touch of a button. Artie Meal Bowls are a mix of highly nutritious freeze-dried and dehydrated whole foods which are proportioned for the pet's caloric needs. Available exclusively on-line and packaged in sealed, serving-sized bowls, which are renewable and/or recyclable, the pet parent need only to add water to the specialty preparation appliance and follow the instructions to deliver a hot meal to the pet in 2-3 minutes.*



## PRESENTING EMERGING COMPANIES

### Genvax Technologies Inc.

Ames, Iowa | [Website](#)

*Genvax Technologies, Inc. is developing self-amplifying mRNA (saRNA) and nanoparticle technology. The company's focus is delivery of custom, rapid-response vaccines to combat endemic livestock diseases. The saRNA vaccines will be developed as a 100% match to the endemic or emerging disease being addressed for custom and targeted vaccination. As such, the company expects to eliminate the need for antiquated, expensive, and ineffective vaccines.*

### Kubanda Cryotherapy Inc.

Baltimore, Maryland | [Website](#)

*Kubanda Cryotherapy Inc will disrupt the veterinary care market by providing a low-cost, non-surgical alternative for removal of masses. Without the need for general anesthesia, the company's technology utilizes carbon dioxide-based cryotherapy to freeze even the largest of masses. The process will lower both the cost and risk to the pet parent and pet while increasing patient retention and revenues for the veterinary clinic. This novel approach promises to increase the number and percentage of pet parents opting to treat masses in their pets.*

### MI:RNA

West Lothian, United Kingdom | [Website](#)

*MI:RNA has developed a highly innovative diagnostic testing solution for a wide range of applications in animal health. Using microRNA (miRNA), an important signaling and immune-regulatory molecules found in all species, the platform offers the ability for early and accurate diagnosis of arising disease as well as evaluation of treatment outcomes. As miRNA allows for diagnosis of disease prior to observation of clinical signs, early detection through screening will provide for better treatment outcomes and improved quality of life in companion animals as well as improved productivity, better welfare, and decreased use of antibiotics in livestock.*

### Novobind Livestock Therapeutics Inc.

British Columbia, Canada | [Website](#)

*Novobind Livestock Therapeutics Inc. is developing alternatives to anti-infectives for livestock, aquaculture, and companion animals. The company's platform of next-generation biologics, termed NanoBodies, targets gastrointestinal pathogens and parasites. Nanobodies are targeted, potent, stable, and scalable allowing the benefits of monoclonal antibodies economically to production animal diseases. The initial targets for the technology are poultry and shrimp diseases.*



ANIMAL HEALTH  
**CORRIDOR  
SUMMIT**

**2023**

# PRESENTING EMERGING COMPANIES

## ReproHealth Technologies

Indianapolis, Indiana | [Website](#)

*ReproHealth Technologies is utilizing biomedical engineering and embryology to improve reproduction in cattle. The company has developed a Bovine Intravaginal Embryo Culture (IVC) device to allow expanded use of embryo transfer in cattle. Based on technology used in humans where it resulted in a pregnancy rate similar to conventional in-vitro fertilization (IVF), the company will allow more cattle producers around the world to take advantage of the more rapid genetic improvement which embryo transfer provides at a cost that more closely resembles that of artificial insemination.*

## Sylvester.ai

Alberta, Canada | [Website](#)

*Sylvester.ai uses the power of machine learning to create a patented feline comfort level classification system and algorithms which measures photos/videos of cats to veterinarian validated facial pain scales. Cats mask pain, discomfort, and stress which makes it difficult for the cat parent to detect these signs. This is compounded by the infrequent veterinary visits for cats so professionals do not have opportunity to examine the pet. Given that cat owners are reactive to health issues, the company will provide a means of detection based on evaluation of cat facial signals.*

## Xeptiva Therapeutics

Montevideo, Uruguay | [Website](#)

*Xeptiva Therapeutics is developing a pipeline of first-in-class immunotherapies to provide healthier aging and treat its related chronic conditions. The company's first product will target osteoarthritis in order to safely reduce the signs of pain. Based on data demonstrated to date, the company expects to address this common ailment in a durable and affordable manner. Following development of this lead product, the company has identified a second product which holds promise for the treatment of atopic dermatitis.*